Results 111 to 120 of about 8,510 (199)

Long-Term Response of Lorlatinib to Leptomeningeal Metastasis in Patients with Anaplastic Lymphoma Kinase Fusion Positive Non-Small Lung Cancer: A Case Report

Case Reports in Oncology
Introduction: Patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) are at increased risk of central nervous system (CNS) metastasis at initial diagnosis and throughout treatment.
Yutaka Fujiwara, Katsuhiro Masago, Reiko Matsuzawa, Teppei Yamaguchi, Naohiro Watanabe, Junichi Shimizu, Eiichi Sasaki, Yoshitsugu Horio   +7 more
doaj   +1 more source

Expression and amplification of HER2 and molecular markers of signal activation in the advanced or metastatic lung carcinoma [PDF]

, 2018
Die Arbeit beleuchtet die Bedeutung des Signalmoleküls HER2 im Rahmen der intrazellulären Signalweiterleitung sowie seine Bedeutung als prognostischer bzw. prädiktiver Marker im fortgeschrittenen bzw.
Huber, Ulrich Cyril
core  

Efficacy of Lorlatinib on Cerebral Metastases in the Management of Alk-Positive Lung Adenocarcinoma, Case Report

Scholars Journal of Medical Case Reports
Bronchial cancers are the leading cause of brain metastases and, in the absence of treatment, the median survival time for patients with bronchial cancer complicated by symptomatic brain metastases is approximately one month.
Abdoul Karim Poudiougou, Hamadoun Traoré, Faman Sano, Imad Taleb, C. Elm’hadi, R. Tanz, Hassan Errihani   +6 more
semanticscholar   +1 more source

Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain [PDF]

Background: Lorlatinib, a third-generation tyrosine kinase inhibitor (TKI), targets both ALK and ROS1 rearrangements in non-small cell lung cancer (NSCLC).
Aguado, Carlos, Aguilar, Andrés, Aguin, Santiago, Alonso, Mirian, Amenedo, Margarita, Arriola, Esperanza, Azkona, Eider, Baena, Javier, Bayona, Cristina, Blasco, Ana, Calles, Antonio, Calvo, Virginia, Cucurull, Marc, De Castro, Javier, Diz-taín, Mpilar, Estival, Anna, Gómez, Ana, Isla, Dolores, Juan-vidal, Oscar, Laura Ortega, Ana, Majem, Margarita, Martín-martorell, Paloma, Martínez-aguillo, Maite, Martínez-banaclocha, Natividad, Mielgo, Xabier, Mosquera, Joaquin, Nadal, Ernest, Reyes, Roxana, Sais, Elia, Santos, Ana, Taus, Álvaro, Villanueva, Noemí   +31 more
core   +1 more source

Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion [PDF]

, 2023
Bironzo, Paolo
core   +1 more source

Current knowledge about mechanisms of drug resistance against ALK inhibitors in non-small cell lung cancer [PDF]

, 2021
Jost, Philipp J., Lindenmann, Joerg, Pichler, Martin, Smolle, Elisabeth, Taucher, Valentin   +4 more
core   +1 more source

Managing lorlatinib together: An overview and practical guide for patients by ALK-positive NSCLC patients and medical experts [PDF]

Adverse event; Anaplastic lymphoma kinase; Non-small cell lung cancerEsdeveniment advers; Cinasa del limfoma anaplàsic; Càncer de pulmó de cèl·lules no petitesEvento adverso; Cinasa del linfoma anaplásico; Cáncer de pulmón de células no ...
Bauer, Todd, FELIP, ENRIQUETA, Goto, Yasushi, Green, Gerald, Liu, Geoffrey, Pronsati, Nancee   +5 more
core   +1 more source

Lorlatinib Induced Non-cardiogenic Pulmonary Edema

Internal medicine
A 71-year-old woman was diagnosed with anaplastic lymphoma kinase-positive metastatic lung adenocarcinoma staged as cT1cN3M1c (8th edition). Treatment with lorlatinib (100 mg) was initiated on a daily basis.
Suzuka Matsuoka, Hiromi Watanabe, Tomoyoshi Inoue, Yukiko Takigawa, Kenichiro Kudo, A. Sato, Ken Sato, Keiichi Fujiwara, Takuo Shibayama   +8 more
semanticscholar   +1 more source

Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report

OncoTarget
ROS1 and RET fusions are targetable mutations that occur in a subset of patients with non-small cell lung cancer (NSCLC). ROS1 and RET have been understood to be independent oncogenic drivers which do not co-occur with other common tyrosine kinase ...
Jenny L Wu, W. Iams
semanticscholar   +1 more source

Treatment of metastatic ALK-positive non-small cell lung cancer: indirect comparison of different ALK inhibitors using reconstructed patient data

Frontiers in Oncology
IntroductionAnaplastic lymphoma kinase (ALK) inhibitors (ALKi) are the standard treatment for metastatic, ALK-positive non-small cell lung cancer (NSCLC).
Vera Damuzzo, Vera Damuzzo, Lorenzo Gasperoni, Luna Del Bono, Andrea Ossato, Andrea Ossato, Alessandro Inno, Andrea Messori, Andrea Messori   +8 more
doaj   +1 more source